Increased cardiovascular mortality after early bilateral oophorectomy

Menopause

Volumn 16, Issue 1, 2009, Pages 15-23

  Rivera, Cathleen M ^a   Grossardt, Brandon R ^a   Rhodes, Deborah J ^a   Brown, Robert D ^b   Roger, Véronique L ^a   Melton, L Joseph ^a   Rocca, Walter A ^a,b  

^a Department of Health Sciences Research   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Age at menopause; Cardiovascular disease; Estrogen treatment; Mortality; Oophorectomy

Indexed keywords

ESTROGEN;

ADULT; AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; MORTALITY; OUTCOME ASSESSMENT; OVARIECTOMY; AGE; COHORT ANALYSIS; FOLLOW UP; HYSTERECTOMY; MIDDLE AGED; OVARY DISEASE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

ADULT; AGE FACTORS; CARDIOVASCULAR DISEASES; COHORT STUDIES; ESTROGENS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYSTERECTOMY; MENOPAUSE; MIDDLE AGED; OVARIAN DISEASES; OVARIECTOMY; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 64049116138     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e31818888f7     Document Type: Article

References (51)

1. Parker WH, Broder MS, Liu Z, Shoupe D, Farquhar C, Berek JS. Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol 2005;106:219-226.
2. Armstrong K, Schwartz JS, Randall T, Rubin SC, Weber B. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol 2004;22:1045-1054.
3. Domchek SM, Friebel TM, Neuhausen SL, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 2006;7:223-229.
4. Shoupe D, Parker WH, Broder MS, Liu Z, Farquhar C, Berek JS. Elective oophorectomy for benign gynecological disorders. Menopause 2007;14:580-585.
5. Parker WH, Broder MS, Liu Z, Shoupe D, Farquhar C, Berek JS. Ovarian conservation at the time of hysterectomy for benign disease. Clin Obstet Gynecol 2007;50:354-361.
6. Shuster LT, Gostout BS, Grossardt BR, Rocca WA. Prophylactic oophorectomy in premenopausal women and long-term health. Menopause Int 2008;4:111-116.
7. Melton LJ 3rd, Bergstralh EJ, Malkasian GD, O'Fallon WM. Bilateral oophorectomy trends in Olmsted County, Minnesota, 1950-1987. Epidemiology 1991;2:149-152.
8. Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ 3rd. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 2006;7:821-828.
9. Speroff T, Dawson NV, Speroff L, Haber RJ. A risk-benefit analysis of elective bilateral oophorectomy: effect of changes in compliance with estrogen therapy on outcome. Am J Obstet Gynecol 1991;164:165-174.
10. Buist DS, Newton KM, Miglioretti DL, et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol 2004;104:1042-1050.
11. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53.
12. Allison MA, Manson JE, Langer RD, et al. Oophorectomy, hormone therapy, and subclinical coronary artery disease in women with hysterectomy: the Women's Health Initiative Coronary Artery Calcium Study. Menopause 2008;15:639-647.
13. Rees MC. Premature menopause: hormone replacement therapy is indeed indicated. BMJ 2008;336:1148.
14. ACOG. Elective and risk-reducing salpingo-oophorectomy. ACOG Practice Bulletin No. 89. Obstet Gynecol 2008;111:231-241.
15. Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 2008;70:200-209.
16. Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007;69:1074-1083.
17. Rocca WA, Grossardt BR, Maraganore DM. The long-term effects of oophorectomy on cognitive and motor aging are age dependent. Neurodegener Dis 2008;5:257-260.
18. Rocca WA, Grossardt BR, Geda YE, et al. Long-term risk of depressive and anxiety symptoms after early bilateral oophorectomy. Menopause 2008;15:1050-1059.
19. Melton LJ 3rd, Crowson CS, Malkasian GD, O'Fallon WM. Fracture risk following bilateral oophorectomy. J Clin Epidemiol 1996;49:1111-1115.
20. Melton LJ 3rd, Khosla S, Malkasian GD, Achenbach SJ, Oberg AL, Riggs BL. Fracture risk after bilateral oophorectomy in elderly women. J Bone Miner Res 2003;18:900-905.
21. Beard CM, Crowson CS, Malkasian GD, O'Fallon WM, Melton LJ 3rd. Cardiovascular disease and cancer risk following bilateral oophorectomy: a population-based study in Rochester, Minnesota. J Womens Health 1995;4:133-141.
22. Melton LJ 3rd. History of the Rochester Epidemiology Project. Mayo Clin Proc 1996;71:266-274.
23. H-ICDA, Hospital Adaptation of ICDA. 2nd ed. Ann Arbor, MI: Commission on Professional and Hospital Activities, 1973.
24. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;115:e69-e171.
25. Gerber Y, Jacobsen SJ, Frye RL, Weston SA, Killian JM, Roger VL. Secular trends in deaths from cardiovascular diseases: a 25-year community study. Circulation 2006;113:2285-2292.
26. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer, 2000.
27. Seliger SL, Longstreth WT Jr. Lessons about brain vascular disease from another pulsating organ, the kidney. Stroke 2008;39:5-6.
28. Howard BV, Kuller L, Langer R, et al. Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the women's health initiative observational study. Circulation 2005;111:1462-1470.
29. Kaplan JR, Adams MR, Anthony MS, Morgan TM, Manuck SB, Clarkson TB. Dominant social status and contraceptive hormone treatment inhibit atherogenesis in premenopausal monkeys. Arterioscler Thromb Vasc Biol 1995;15:2094-2100.
30. Kaplan JR, Manuck SB. Ovarian dysfunction, stress, and disease: a primate continuum. ILAR J 2004;45:89-115.
31. Jayachandran M, Karnicki K, Miller RS, Owen WG, Korach KS, Miller VM. Platelet characteristics change with aging: role of estrogen receptor beta. J Gerontol A Biol Sci Med Sci 2005;60:815-819.
32. Williams JK, Anthony MS, Honore EK, et al. Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol 1995;15:827-836.
33. Last JM. International epidemiological association. A Dictionary of Epidemiology, 4th ed. New York, NY: Oxford University Press, 2001.
34. Howe HL. Age-specific hysterectomy and oophorectomy prevalence rates and the risks for cancer of the reproductive system. Am J Public Health 1984;74:560-563.
35. Snowdon DA, Kane RL, Beeson WL, et al. Is early natural menopause a biologic marker of health and aging? Am J Public Health 1989;79:709-714.
36. Jacobsen BK, Nilssen S, Heuch I, Kvale G. Does age at natural menopause affect mortality from ischemic heart disease? J Clin Epidemiol 1997;50:475-479.
37. de Kleijn MJ, van der Schouw YT, Verbeek AL, Peeters PH, Banga JD, van der Graaf Y. Endogenous estrogen exposure and cardiovascular mortality risk in postmenopausal women. Am J Epidemiol 2002;155:339-345.
38. Jacobsen BK, Knutsen SF, Fraser GE. Age at natural menopause and total mortality and mortality from ischemic heart disease: the Adventist Health Study. J Clin Epidemiol 1999;52:303-307.
39. Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Post-menopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006;13:265-279.
40. Lobo RA. Surgical menopause and cardiovascular risks. Menopause 2007;14:562-566.
41. Dubey RK, Imthurn B, Barton M, Jackson EK. Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Cardiovasc Res 2005;66:295-306.
42. Lokkegaard E, Jovanovic Z, Heitmann BL, Keiding N, Ottesen B, Pedersen AT. The association between early menopause and risk of ischaemic heart disease: influence of hormone therapy. Maturitas 2006;53:226-233.
43. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477.
44. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007;356:2591-2602.
45. Harman SM, Naftolin F, Brinton EA, Judelson DR. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence. Ann N Y Acad Sci 2005;1052:43-56.
46. Manson JE, Bassuk SS, Harman SM, et al. Postmenopausal hormone therapy: new questions and the case for new clinical trials. Menopause 2006;13:139-147.
47. Beard CM, Melton LJ 3rd, Cedel SL, Richelson LS, Riggs BL. Ascertainment of risk factors for osteoporosis: comparison of interview data with medical record review. J Bone Miner Res 1990;5:691-699.
48. Goraya TY, Jacobsen SJ, Belau PG, Weston SA, Kottke TE, Roger VL. Validation of death certificate diagnosis of out-of-hospital coronary heart disease deaths in Olmsted County, Minnesota. Mayo Clin Proc 2000;75:681-687.
49. Marks NF, Shinberg DS. Socioeconomic status differences in hormone therapy. Am J Epidemiol 1998;148:581-593.
50. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003;348:645-650.
51. Lynch JW, Kaplan GA, Cohen RD, Tuomilehto J, Salonen JT. Do cardiovascular risk factors explain the relation between socioeconomic status, risk of all-cause mortality, cardiovascular mortality, and acute myocardial infarction? Am J Epidemiol 1996;144:934-942.